The search for disease-modifying treatment for Alzheimer's disease

Neurology

Volumn 48, Issue 5 SUPPL. 6, 1997, Pages

  Aisen, Paul S ^a   Davis, Kenneth L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; AZATHIOPRINE; BETA INTERFERON; CALCIUM CHANNEL BLOCKING AGENT; CHELATING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; ENZYME ACTIVATOR; ENZYME INHIBITOR; FREE RADICAL; GLUCOCORTICOID; GLUTAMATE RECEPTOR ANTAGONIST; HYDROXYCHLOROQUINE; IDEBENONE; LETEPRINIM; LEVACECARNINE; METHOTREXATE; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; PROPENTOFYLLINE; SALAZOSULFAPYRIDINE; SELEGILINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; CLINICAL TRIAL; HUMAN; INFLAMMATION; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; OXIDATIVE STRESS; PREVENTION; PRIORITY JOURNAL; PROTEIN PROCESSING;

EID: 0030998896     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.48.5_suppl_6.35s     Document Type: Article

References (89)

1. Davis KL, Thal LJ, Gamzu ER, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992;327:1253-1259.
2. Price DL, Koliatsos VE, Sisodia SS, et al. Amyloid-related proteins and nerve growth factor in Alzheimer's disease and animal models. Clin Neuropharmacol 1991;14:S9-S14.
3. Hefti F. Development of effective therapy for Alzheimer's disease based on neurotrophic factors. Neurobiol Aging 1994;15: S193-S194.
4. Markowska AL, Koliatsos VE, Breckler SJ, Price DL, Otton DS. Human nerve growth factor improves spatial memory in aged but not young rats. J Neurosci 1994;14:4815-4824.
5. Dekker AJ, Winkler J, Ray J, Thai LJ, Gage FH. Grafting of nerve growth factor-producing fibroblasts reduces behavioral deficits in rats with lesions of the nucleus basalis magnocellularis. Neuroscience 1994;60:299-309.
6. Kramer R, Zhang Y, Gehrmann J, Gold R, Thoenen H, Wekerle H. Gene transfer through the blood-nerve barrier: NGF-engineered neuritogenic T lymphocytes attenuate experimental autoimmune neuritis. Nature Med 1995;1:1162-1166.
7. Martinez-Serrano A, Fischer W, Bjorklund A. Reversal of age-dependent cognitive impairments and cholinergic neuron atrophy by NGF-secreting neural progenitors grafted to the basal forebrain. Neuron 1995;15:473-484.
8. Middlemiss PJ, Glasky AJ, Rathbone MP, Werstuik E, Hindley S, Gyspers J. AIT-082, a unique purine derivative, enhances nerve growth factor mediated neurite outgrowth from PC12 cells. Neurosci Lett 1995;199:131-134.
9. Glasky AJ, Melchior CL, Pirzadeh B, Heydari N, Ritzmann RF. Effect of AIT-082, a purine analog, on working memory in normal and aged mice. Pharmacol Biochem Behav 1994;47: 325-329.
10. Games D, Adams D, Alessandrini R, et al. Development of neuropathology similar to Alzheimer's disease in transgenic mice overexpressing the 717V-F β-amyloid precursor protein. Nature 1995;373:523-527.
11. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature Med 1996;2:864-870.
12. Golde TE, Estus S, Younkin LH, Selkoe DJ, Younkin SG. Processing of the amyloid precursor for potentially amyloidogenic derivatives. Science 1992;155:728-730.
13. Checler F. Processing of the beta-amyloid precursor protein and its regulation in Alzheimer's disease. J Neurochem 1995; 65:1431-1444.
14. Gandy S, Greengard P. Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities. Trends Pharmacol Sci 1992;13:108-113.
15. Xu HX, Greengard P, Gandy S. Regulated formation of Golgi secretory vesicles containing Alzheimer β-amyloid precursor protein. J Biol Chem 1995;270:23243-23245.
16. Xu HX, Sweeney D, Greengard P, Gandy S. Metabolism of Alzheimer beta-amyloid precursor protein: regulation by protein kinase A in intact cells and in a cell-free system. Proc Natl Acad Sci USA 1994;93:4081-4084.
17. Buxbaum JD, Oishi M, Chen HI, et al. Cholinergic agonists and interleukin-1 regulate processing and secretion of the Alzheimer β/A4 amyloid protein precursor. Proc Natl Acad Sci USA 1992;89:10075-10078.
18. Lahiri DK, Lewis S, Farlow MR. Tacrine alters the secretion of the beta-amyloid precursor protein in cell lines. J Neurosci Res 1994;37:777-787.
19. Nitsch RM, Wurtman RJ, Growdon JH. Regulation of APP processing: potential for the therapeutical reduction of brain amyloid burden. Ann NY Acad Sci 1996;777:175-182.
20. Haroutunian V, Greig N, Pei X-F, et al. Pharmacological modulation of Alzheimer's β-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic lesions. Mol Brain Res (in press).
21. Nuydens R, De Jong M, Nuyens R, Cornelissen F, Geerts H. Neuronal kinase stimulation leads to aberrant tau phosphorylation and neurotoxicity. Neurobiol Aging 1995;16:465-475.
22. Lee VMY. Regulation of tau phosphorylation in Alzheimer's disease. Ann NY Acad Sci 1996;777:107-113.
23. Halliwell B. Oxygen radicals as key mediators in neurological disease: fact or fiction? Ann Neurol 1992;32:S10-S15.
24. Friedlich AL, Butcher LL. Involvement of free oxygen radicals in β-amyloidosis: an hypothesis. Neurobiol Aging 1994;15: 443-455.
25. Benzi G, Moretti A. Are reactive oxygen species involved in Alzheimer's disease? Neurobiol Aging 1995;16:661-674.
26. Subbarao KV, Richardson JS, Ang LC. Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J Neurochem 1990;55:342-345.
27. Hensley K, Carney JM, Mattson MP, et al. A model for β-amyloid aggregation and neurotoxicity based on free-radical generation by the peptide: relevance to Alzheimer disease. Proc Natl Acad Sci USA 1994;91:3270-3274.
28. Tomiyama T, Shoji A, Kataoka K, et al. Inhibition of amyloid β protein aggregation and neurotoxicity by rifampicin - its possible function as a hydroxyl radical scavenger. J Biol Chem 1996;271:6839-6844.
29. Bruce AJ, Malfroy B, Baudry M. β-Amyloid toxicity in organotypic hippocampal cultures: protection by EUK-8, a synthetic catalytic free radical scavenger. Proc Natl Acad Sci USA 1996; 93:2312-2316.
30. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362:59-62.
31. Hall ED. Novel inhibitors of iron-dependent lipid peroxidation for neurodegenerative disorders. Ann Neurol 1992;32:S137-S142.
32. Yoshida S, Busto R, Watson BD, Santiso M, Ginsberg MD. Postischemic cerebral lipid peroxidation in vitro: modification by vitamin E. J Neurochem 1985;44:1593-1601.
33. Hara H, Kato H, Kogure K. Protective effect of alpha-tocopherol on ischemic neuronal damage in the gerbil hippocampus. Brain Res 1990;510:335-338.
34. Tariot PN, Sunderland T, Weingartner H, et al. Cognitive effects of selegiline in Alzheimer's disease. Psychopharmacology (Berl) 1987;91:489-495.
35. Mangoni A, Grassi MP, Frattola L, et al. Effects of a MAO-B inhibitor in the treatment of Alzheimer's disease. Eur Neurol 1991;31:100-107.
36. Knoll J. Deprenyl (selegiline): the history of its development and pharmacologic action. Acta Neurol Scand 1983;95(suppl): 57-80.
37. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.
38. Aisen PS, Davis KL. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am J Psychiatry 1994; 151:1105-1113.
39. 1-antichymotrypsin serum levels in a subset of nondemented first-degree relatives of Alzheimer's disease patients. Dementia 1995;6:17-20.
40. Matsubara E, Hirai S, Amari M, et al. Alpha-1-anti-chymotrypsin as a possible biochemical marker for Alzheimer-type dementia. Ann Neurol 1990;28:561-567.
41. 1-antichymotrypsin in Down's syndrome and Alzheimer's disease. Ann Neurol 1992;32:193-197.
42. 1-antichymotrypsin and Alzheimer's disease. Neurobiol Aging 1994;15:21-27.
43. Loeffler DA, LeWitt PA, Juneau PL, Perry MF, Brickman CM. Increased concentrations of complement component C3a in Alzheimer's disease CSF [abstract]. Neurology 1996;46:A161.
44. Campbell IL, Abraham CR, Masliah E, et al. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin-6. Proc Natl Acad Sci USA 1993;90:10061-10065.
45. Tsuzuki K, Fukatsu R, Takamaru Y, et al. Co-localization of amyloid-associated proteins with amyloid β in rat soleus muscle in chloroquine-induced myopathy: a possible model for amyloid β formation in Alzheimer's disease. Brain Res 1995; 699:260-265.
46. 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature 1994;372:92-94.
47. Webster S, Glabe C, Rogers J. Multivalent binding of complement protein C1Q to the amyloid β-peptide (Aβ) promotes the nucleation phase of Aβ aggregation. Biochem Biophys Res Commun 1995;217:869-875.
48. Oda T, Lehrer-Graiwer J, Finch CE, Pasinetti GM. Complement and β-amyloid (Aβ) neurotoxicity in vitro: a model for Alzheimer disease. Alzheimers Res 1995;1:29-34.
49. Sheng JG, Mrak RE, Griffin WST. Microglial interleukin-1α expression in brain regions in Alzheimer's disease: correlation with neuritic plaque distribution. Neuropathol Appl Neurobiol 1995;21:290-301.
50. Giulian D, Li J, Leara B, Keenen C. Phagocytic microgha release cytokines and cytotoxins that regulate the survival of astrocytes and neurons in culture. Neurochem Int 1994;25: 227-233.
51. London JA, Biegel D, Pachter JS. Neurocytopathic effects of beta-amyloid-stimulated monocytes: a potential mechanism for central nervous system damage in Alzheimer disease. Proc Natl Acad Sci USA 1996;93:4147-4152.
52. McGeer PL, McGeer E, Rogers J, Sibley J. Anti-inflammatory drugs and Alzheimer disease. Lancet 1990;335:1037.
53. Andersen K, Launer LJ, Ott A, Hoes AW, Breteler NMB, Hofman A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam study. Neurology 1995;45:1441-1445.
54. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 1995;45:51-55.
55. Lucca U, Tettamanti M, Forloni G, Spagnoli A. Nonsteroidal antiinflammatory drug use in Alzheimer's disease. Biol Psychiatry 1994;36:854-856.
56. Breitner JC, Gau BA, Welsh KA, et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology 1994;44:227-232.
57. 2 blocking drugs. Neurobiol Aging 1995;16:523-530.
58. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology (in press).
59. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43: 1609-1611.
60. O'Banion MK, Winn VD, Young DA. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci USA 1992;89:4888-4892.
61. Cao C, Matsumura K, Yamagata K, Watanabe Y. Induction by lipopolysaccharide of cyclooxygenase-2 mRNA in rat brain: its possible role in the febrile response. Brain Res 1995;697:187-196.
62. Hertting G, Seregi A. Formation and function of eicosanoids in the central nervous system. Ann NY Acad Sci 1989;559:84-99.
63. Yamagata K, Andreasson KI, Kaufmann WE, Barnes CA, Worley PF. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 1993;11:371-386.
64. Kaufmann WE, Worley PF, Pegg J, Bremer M, Isakson P. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci USA 1996;93:2317-2321.
65. Adams J, Collaço-Moraes Y, de Belleroche J. Cyclooxygenase-2 induction in cerebral cortex: an intracellular response to synaptic excitation. J Neurochem 1996;66:6-13.
66. Sasaki T, Nakagomi T, Kirino T, et al. Indomethacin ameliorates ischemic neuronal damage in the gerbil hippocampal CAl sector. Stroke 1988;19:1399-1403.
67. Aisen PS, Marin D, Altstiel L, et al. A pilot study of prednisone in Alzheimer's disease. Dementia 1996;7:201-206.
68. Aisen PS, Altstiel L, Marin D, Davis K. Treatment of Alzheimer's disease with prednisone: results of pilot studies and design of multicenter trial [abstract]. J Am Geriatr Soc 1995; 43:SA27.
69. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
70. Bennett EL, Alberti MH, Flood JF. Uptake of [3H] colchicine into brain and liver of mouse, rat, and chick. Pharmacol Biochem Behav 1981;14:863-869.
71. Berliner RW, Earle DP Jr, Taggart JV, et al. Studies on the chemotherapy of the human malarias. VI. The physiological disposition, antimalarial activity, and toxicity of several derivatives of 4-amino quinoline. J Clin Invest 1948;27:98-107.
72. Aisen PS, Marin D, Fusco M, Baruch B, Ryan T, Davis KL. A pilot study of colchicine in Alzheimer's disease. Alzheimers Res 1996;2:153-156.
73. Forloni G, Angeretti N, Smiroldo S. Neuroprotective activity of acetyl-L-carnitine: studies in vitro. J Neurosci Res 1996;37: 92-96.
74. Carta A, Calvani M, Bravi D, Bhuachalla SN. Acetyl-L-carnitine and Alzheimer's disease: pharmacological considerations beyond the cholinergic sphere. Ann NY Acad Sci 1996; 695:324-326.
75. Sano M, Bell K, Cote L, et al. Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's disease. Arch Neurol 1992;49:1137-1141.
76. Bruno V, Battaglia G, Copani A, Sortino MA, Canonico PL, Nicoletti F. Protective action of idebenone against excitotoxic degeneration in cultured cortical neurons. Neurosci Lett 1994; 178:193-196.
77. Wieland E, Schutz E, Armstrong VW, Kuthe F, Heller C, Oellerich M. Idebenone protects hepatic microsomes against oxygen radical-mediated damage in organ preservation solutions. Transplantation 1995;60:444-451.
78. Nabeshima T. Nerve growth factor strategy and preparation of animal model for Alzheimer-type senile dementia. Yakugaku Zasshi 1995;115:499-512.
79. Gillis JC, Benefield P, McTavish D. Idebenone: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders. Drugs Aging 1994;5:133-152.
80. Bergamasco B, Scarzella L, La Commare P. Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer type. Funct Neurol 1994;9: 161-168.
81. Fredholm BB, Lindstrom K, Wallman-Johansson A. Propentofylline and other adenosine transport inhibitors increase the efflux of adenosine following electrical or metabolic stimulation of rat hippocampal slices. J Neurochem 1994;62:563-573.
82. McRae A, Rudolphi KA, Schubert P. Propentofylline depresses amvloid and Alzheimer's CSF microglial antigens after ischaemia. Neuroreport 1994;5:1193-1196.
83. 2+ homeostasis in Alzheimer's disease. Trends Neurosci 1993;16:409-414.
84. Tollefson GD. Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia. Biol Psychiatry 1990;27:1133-1142.
85. Disterhoft JF, Moyer JR Jr, Thompson LT. The calcium rationale in aging and Alzheimer's disease. Ann NY Acad Sci 1994; 747:382-406.
86. Lawlor BA, Davis KL. Does modulation of glutamatergic function represent a viable therapeutic strategy in Alzheimer's disease? Biol Psychiatry 1992;31:337-350.
87. Klunk WE, Debnath ML, Pettegrew JW. Chrysamine-G binding to Alzheimer and control brain: autopsy study of a new amyloid probe. Neurobiol Aging 1995;16:541-548.
88. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging. Neurology (in press).
89. Aisen PS. Anti-inflammatory therapy in Alzheimer's disease. Dementia (Japan) 1995;9:173-182.